当前位置：
X-MOL 学术
›
Cancer Manage. Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer
Cancer Management and Research ( IF 3.3 ) Pub Date : 2021-09-10 , DOI: 10.2147/cmar.s314369 Daoming Zhang 1 , Yuan Li 1 , Haoyue Li 2 , Tian Tang 1 , Yongfa Zheng 1 , Xufeng Guo 1 , Ximing Xu 1
Cancer Management and Research ( IF 3.3 ) Pub Date : 2021-09-10 , DOI: 10.2147/cmar.s314369 Daoming Zhang 1 , Yuan Li 1 , Haoyue Li 2 , Tian Tang 1 , Yongfa Zheng 1 , Xufeng Guo 1 , Ximing Xu 1
Affiliation
Objective: To evaluate the value of serum complement component 1q (C1q) levels in predicting the efficacy of combined immunotherapy in patients with lung cancer.
Methods: A total of 42 patients with lung cancer who received combined immunotherapy in the cancer center of Renmin Hospital of Wuhan University were included in this study. The clinical data of serum C1q and lactate dehydrogenase (LDH) levels before and three weeks after immunotherapy were collected.
Results: Response evaluation showed that the number of patients with complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) was 0 (0%), 26 (61.9%), 14 (33.3%), and 2 (4.8%), respectively. The CR/PR group (patients with CR or PR) showed higher pC1q (C1q level before immunotherapy) and iC1q (C1q level 3 weeks after immunotherapy) than the SD/PD group (patients with SD or PD). The LDH reduction (96.2%) and C1q increment (84.6%) in the CR/PR group 3 weeks after immunotherapy were higher than those of the SD/PD group, and the differences were statistically significant. Logistic regression analysis indicated that pC1q, iC1q, and LDH level trends 3 weeks after the treatment were significantly correlated to the efficacy of combined immunotherapy with odds ratios of 8.185, 5.500, and 0.031, respectively.
Conclusion: High C1q levels before immunotherapy and increased C1q levels and decreased LDH levels 3 weeks afterward suggest good therapeutic effects of combined immunotherapy in patients with lung cancer. Serum C1q levels have certain clinical significance in predicting the efficacy of combined immunotherapy.
Keywords: immunotherapy, efficacy prediction, complement component 1q
中文翻译：
补体成分 1q 水平在预测肺癌患者联合免疫疗法疗效中的初步研究
目的：评价血清补体成分1q（C1q）水平在预测肺癌患者联合免疫治疗疗效中的价值。
方法：纳入武汉大学人民医院肿瘤中心接受联合免疫治疗的肺癌患者42例。收集免疫治疗前后3周血清C1q和乳酸脱氢酶（LDH）水平的临床资料。
结果：疗效评价显示，完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）和疾病进展（PD）的患者数分别为0（0%）、26（61.9%）、14（ 33.3%) 和 2 (4.8%)。CR/PR 组（CR 或 PR 患者）显示更高的pC1q（免疫治疗前的 C1q 水平）和i C1q（免疫治疗后 3 周的 C1q 水平）高于 SD/PD 组（患有 SD 或 PD 的患者）。CR/PR组免疫治疗后3周LDH减少量（96.2%）和C1q增加量（84.6%）均高于SD/PD组，差异有统计学意义。Logistic回归分析表明，治疗后3周p C1q、i C1q和LDH水平趋势与联合免疫治疗的疗效显着相关，优势比分别为8.185、5.500和0.031。
结论：免疫治疗前较高的 C1q 水平和 3 周后 C1q 水平升高和 LDH 水平降低表明联合免疫治疗对肺癌患者的良好治疗效果。血清C1q水平在预测联合免疫治疗疗效方面具有一定的临床意义。
关键词：免疫治疗，疗效预测，补体成分 1q
更新日期：2021-09-10
Methods: A total of 42 patients with lung cancer who received combined immunotherapy in the cancer center of Renmin Hospital of Wuhan University were included in this study. The clinical data of serum C1q and lactate dehydrogenase (LDH) levels before and three weeks after immunotherapy were collected.
Results: Response evaluation showed that the number of patients with complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) was 0 (0%), 26 (61.9%), 14 (33.3%), and 2 (4.8%), respectively. The CR/PR group (patients with CR or PR) showed higher pC1q (C1q level before immunotherapy) and iC1q (C1q level 3 weeks after immunotherapy) than the SD/PD group (patients with SD or PD). The LDH reduction (96.2%) and C1q increment (84.6%) in the CR/PR group 3 weeks after immunotherapy were higher than those of the SD/PD group, and the differences were statistically significant. Logistic regression analysis indicated that pC1q, iC1q, and LDH level trends 3 weeks after the treatment were significantly correlated to the efficacy of combined immunotherapy with odds ratios of 8.185, 5.500, and 0.031, respectively.
Conclusion: High C1q levels before immunotherapy and increased C1q levels and decreased LDH levels 3 weeks afterward suggest good therapeutic effects of combined immunotherapy in patients with lung cancer. Serum C1q levels have certain clinical significance in predicting the efficacy of combined immunotherapy.
Keywords: immunotherapy, efficacy prediction, complement component 1q
中文翻译：
补体成分 1q 水平在预测肺癌患者联合免疫疗法疗效中的初步研究
目的：评价血清补体成分1q（C1q）水平在预测肺癌患者联合免疫治疗疗效中的价值。
方法：纳入武汉大学人民医院肿瘤中心接受联合免疫治疗的肺癌患者42例。收集免疫治疗前后3周血清C1q和乳酸脱氢酶（LDH）水平的临床资料。
结果：疗效评价显示，完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）和疾病进展（PD）的患者数分别为0（0%）、26（61.9%）、14（ 33.3%) 和 2 (4.8%)。CR/PR 组（CR 或 PR 患者）显示更高的pC1q（免疫治疗前的 C1q 水平）和i C1q（免疫治疗后 3 周的 C1q 水平）高于 SD/PD 组（患有 SD 或 PD 的患者）。CR/PR组免疫治疗后3周LDH减少量（96.2%）和C1q增加量（84.6%）均高于SD/PD组，差异有统计学意义。Logistic回归分析表明，治疗后3周p C1q、i C1q和LDH水平趋势与联合免疫治疗的疗效显着相关，优势比分别为8.185、5.500和0.031。
结论：免疫治疗前较高的 C1q 水平和 3 周后 C1q 水平升高和 LDH 水平降低表明联合免疫治疗对肺癌患者的良好治疗效果。血清C1q水平在预测联合免疫治疗疗效方面具有一定的临床意义。
关键词：免疫治疗，疗效预测，补体成分 1q
京公网安备 11010802027423号